Skip to main content

Therapeuticsmd Inc(TXMD-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low2.15
Day High2.28
Open:2.28
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Therapeuticsmd Inc

Select a category then submit the form to load news
Tipranks
TherapeuticsMD Approves Key Proposals at Annual Meeting
Tipranks
TherapeuticsMD Reports Q3 2025 Financial Results
Business Wire
TherapeuticsMD Announces Third Quarter 2025 Financial Results
Tipranks
TherapeuticsMD Reports Q2 2025 Financial Results
Motley Fool
TherapeuticsMD Swings to Profit in Q2
Business Wire
TherapeuticsMD Announces Second Quarter 2025 Financial Results
Business Wire
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
Business Wire
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
Barchart
Pre-Market Brief: Stocks Mixed As Labor Market Strength Weigh On Sentiment
Wall Street - shutterstock_1321462400
Business Wire
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
Business Wire
TherapeuticsMD Announces Third Quarter 2022 Financial Results
Business Wire
TherapeuticsMD Announces Additional $7 Million Private Placement
Business Wire
TherapeuticsMD Announces $7 Million Private Placement
Business Wire
TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers
Motley Fool
TherapeuticsMD, Inc. (TXMD) Q2 2022 Earnings Call Transcript
Business Wire
TherapeuticsMD Announces Second Quarter 2022 Financial Results
Business Wire
CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors
Business Wire
TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022
Business Wire
TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital
Business Wire
TherapeuticsMD Announces Expiration of Tender Offer
PR Newswire
EW Healthcare Partners Announces Extension of TherapeuticsMD Tender Offer
Business Wire
THERAPEUTICSMD INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TherapeuticsMD, Inc. - TXMD
Best Stocks
Hanesbrands Discloses Ransomware Attack
Business Wire
TXMD Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of TherapeuticsMD, Inc. Is Fair to Shareholders
Business Wire
TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD
Business Wire
TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®
Motley Fool
TherapeuticsMD, Inc. (TXMD) Q1 2022 Earnings Call Transcript
Business Wire
TherapeuticsMD Announces First Quarter 2022 Financial Results
Business Wire
TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022
Business Wire
TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million

Profile

TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.